We envision our initial product to enter the rare cancer therapy discovery market within the next 12 months, followed by our products for the stem cell therapy research markets in the next 24
months. Simultaneously, we are building a portfolio of patented complementary, future-poised unique technologies driving rapid rare cancer and stem cell therapies to patients who urgently
 require it.